Aims. We consider the nature of retinal dysfunction in streptozotocin rats and assess the functional benefits of administering an angiotensin enzyme inhibitor or an inhibitor of advanced glycation end product formation. Methods. Sprague-Dawley rats (n=44) were randomly assigned to control (C=12, C p =4, C a =4) and diabetic groups (Streptozotocin, D=24). Diabetes was diagnosed based on a range of physiological and biochemical parameters at 4, 8 and 12 weeks. Streptozotocin animals were administered insulin daily (4 units protophane). Animals were treated with either an Angiotensin Converting Enzyme inhibitor (perindopril, C p =4, D p =8) or an inhibitor of advanced glycation end product formation (aminoguanidine, C a =4, D a =8). Dark-adapted electroretinograms were measured on anaesthetized animals at 12 weeks following streptozotocin treatment. Photoreceptoral and inner retinal responses were extracted, modelled and compared using ANOVA.
. Similar oscillatory potential deficits have also been reported, soon after the induction of diabetes, in a rat model of Type 1 diabetes [9, 10] . The above electrophysiological studies localize neuronal deficits to the inner retina; however, other studies report the presence of photoreceptoral dysfunction soon after diabetogenesis [11] . More recently, photoreceptor abnormalities have been found in diabetic humans, although vascular changes in these retinae complicates the interpretation of these findings [12] .
Psychophysical measurements of color sensitivity [13, 14] have shown altered thresholds in diabetic patients without retinopathy. Additionally, nerve fibre loss and anomalies of glial cell function and glutamate metabolism have also been observed in diabetic rats [15] . In spite of the conflicting electrophysiological data, the above studies support the contention that neural dysfunction occurs independent of, or at least in conjunction with, the vasculopathy. Consistent with both vascular and neuronal involvement, modulation of the renin-angiotensin system has been shown to have a neuroprotective role [16, 17, 18] . Reduced levels of diabetic retinopathy have been reported using an Angiotensin Converting Enzyme (ACE) as an adjunct to traditional glucose control, in the HOPE multi-centre trial [17] .
The streptozotocin (STZ) rat model of diabetes could serve as a useful model for considering the nature of retinal dysfunction in the diabetic retina prior to the advent of patent vasculopathy [19] . The following study examines photoreceptoral-P3 and inner retinal (postreceptoral-P2, oscillatory potentials) function in rats, 12 weeks following STZ injection. Additionally, we consider the effectiveness of an ACE inhibitor, known to have neuroprotective activity, at restoring any functional deficits induced by STZ treatment.
Materials and methods
All experimental protocols in this study were approved by our institutional ethics committee and conformed to the NHMRC Principles of Laboratory Animal Care. A cohort of 44 Sprague-Dawley rats (200-250 gm) were fasted overnight and randomized to receive either streptozotocin (STZ 50 mg/kg, D=24) or citrate buffer (C=20) by intravenous injection in the tail vein. Diabetes was diagnosed based on a range of physiological and biochemical parameters taken at 4, 8 and 12 weeks. These included: elevated blood glucose concentrations (>15 mmol/l), abnormal glycosylated haemoglobin (HBA 1c >7.0%), polyuria (>40 ml urine volume/24 h) and polydypsia (>60 ml fluid intake/24 h). All STZ-treated animals were administered insulin daily (4 units of human protophane at 9 am) to mimic the human condition. Fluid intake and urine volume was collected using metabolic cages over a 24-h period at time points described above. Body weight was measured weekly. Animals from each group [C=12 (non STZ), D=8 (STZ-treated)] were used to evaluate the specific effects of the diabetic milieu, whereas the remaining animals were treated with drugs. Medication was with either an ACE inhibitor (perindopril, Servier Laboratories, Paris, France, 6 mg/kg: C p =4, D p =8) or an inhibitor of advanced glycation end product formation (aminoguanidine, Regis Technologies, Morton Grove, Ill., USA, 800 mg/kg: C a =4, D a =8). Medications were administered to animals via drinking water. The varying body weights and water intakes were taken into account in determining the appropriate drug dosage for control (perindopril, 0.6 mg/ml: aminoguanidine, 11 mg/ml) and STZ treated (perindopril, 0.25 mg/ml: aminoguanidine, 4 mg/ml) groups to equate drug intake. Our purpose for using the latter drug (aminoguanidine) was to include a group receiving an agent known to have vasoprotective effects without a strong neuromodulatory action. By contrasting the effects found with perindopril against those from aminoguanidine we can consider the hypothesis that ACE inhibition is acting via a neuroprotective mechanism.
Electroretinography. Retinal function was measured at 12 weeks following diabetogenesis with electroretinograms (ERG) collected over an ensemble of light intensities (0.7 to 2.5 log cd·s·m −2 ) following overnight dark-adaptation (>12 h). Animals were anaesthetized under dim red light (λ max =650 nm) using a mixture of ketamine and xylazine (60:5 mg/kg, Troy Laboratory, Frenchs Forest, NSW, Australia). Mydriasis (≥4 mm) was achieved with tropicamide (Mydriacyl 0.5%, Allergan, Frenchs Forest, NSW, Australia) and corneal anesthesia with proxymetacaine (Ophthetic 0.5%, Allergan, Frenchs Forest, NSW, Australia). Flash ERGs (white) were recorded with silver-silver chloride electrodes referenced to a stainless steel ground inserted in the tail. Responses were amplified (gain ×1000; −3 dB at 0.1 and 3000 Hz, P55 Grass instruments, West Warwick, R.I., USA) and digitized at 2 kHz. A commercial photographic flash unit (285 V, Vivitar Photographics, Newbury Park, Calif., USA) was delivered via a Ganzfeld sphere to produce an unfiltered photopic exposure of 3.5 log cd·s·m −2 , which was attenuated using calibrated neutral density filters (Kodak Wratten, Eastman Kodak, Rochester, N.Y., USA).
Photoreceptoral function. The ERG waveform (Fig. 1A) is characterized by the negative going photoreceptoral response or a-wave followed by a positive postreceptoral deflection or b-wave on which can be seen many small oscillations (oscillatory potentials). For this study we model the leading edge of the a-wave using a modified computational description of the phototransduction cascade as given by Equation 1 [20] , (1) where, P3 is the summed rod photocurrent as a function of luminous energy, i (cd·s·m −2 ) and time t (s) and Rm P3 (µV) is its saturated amplitude. Sensitivity (S, m 2 ·cd −1 s −3 ) is scaled by i, whereas t d (s) is a delay which includes biochemical and other recording latencies. This model was fitted to the raw data for an ensemble of luminous energies (0.7 to 2.5 log cd·s·m −2 ) up to the first minimum of each a-wave. The delay t d was fixed at 2.75 ms being the average value found in our normal group. Parameter optimization in all animals was achieved by floating Rm P3 and S (fixed t d ), and minimizing the root-mean-square error term with the solver module of an Excel spreadsheet (Microsoft, Redmond, W.Va., USA). The model was applied to the raw data up to the minimum of each a-wave as shown by the symbols, whereas the lines represent the modelled response (Fig. 1B,C) .
Inner retinal function. The postreceptoral-P2 component is generally believed to originate from the inner retina. The postreceptoral-P2 was exposed by digital subtraction of the modelled photoreceptoral P3 from the raw waveform ( Fig. 2A ) [21] . The isolated postreceptoral-P2 potential is subsequently which represents the multiplication of a gaussian envelope (Eq. 2a) with a sine wave carrier (Eq. 2b) [22] .
As a function of time (x), the gaussian envelope (Eq. 2a) is described by its maximum amplitude (a, OP amplitude, µV), peak envelope position (m, OP implicit time, ms) and spread (s, ms). The sine wave carrier (Eq. 2b) is described by its frequency (h, Hz) and phase relative to the start of the waveform (p, degrees). Fitting was achieved by floating all parameters and minimizing the mean square error term using a LevenbergMarquardt optimization routine.
Statistics. Statistical comparisons were made for the main effects by ANOVA with a Fischer's PLSD post-hoc test used to identify differences between means. A p value of 0.05 was considered statistically significant.
Results
Twelve weeks following STZ injections, treated rats developed characteristics typical of diabetes, showing increased blood glucose concentration, increased glycosylated haemoglobin, reduced body weight, as well . Perindopril (D p , ▲ ▲) treatment fully ameliorated streptozotocin induced photoreceptoral dysfunction, whereas aminoguanidine (D a , ■ ■) showed no improvement. Both perindopril (C p , • centre) and aminoguanidine (C a , • right) drugs had no effect on Rm P3 in control animals. Reference lines show mean (solid) and 95% confidence limits (dotted) of the mean control photoreceptoral-P3 amplitude. E Phototransduction sensitivity (log S) was unaffected by streptozotocin treatment and showed no change with either perindopril or aminoguanidine therapy described in terms of it baseline to peak amplitude and implicit time (stimulus onset to peak).
Oscillatory potentials were isolated by digitally subtracting the a-wave and b-wave from the raw data and band-pass filtering (55-250 Hz, 512-tap FIR filter, Blackman window) the resultant waveform [22] . Following OP extraction we modelled the data in the time domain using a Gabor function (Eq. 2c), (Table 1) . Aminoguanidine therapy in diabetic animals produced a reduction in blood glucose and water intake but failed to normalize these values to those of the control animals. Perindopril treatment of diabetic animals produced improvements in all indices, compared with the untreated diabetic group, except body weight ( Table 1 ). The supply of both aminoguanidine and perindopril to control animals did not significantly alter any of the indices measured in this study.
STZ treatment induces a generalized retinal dysfunction.
One of the findings of this study is that following STZ treatment, a loss of retinal function was observed as shown by the representative waveforms in Fig. 1A . This functional loss was particularly manifest in the photoreceptoral-P3 component of the ERG as shown by the representative phototransduction model fits (lines) to the raw data (symbols) in Fig. 1B . The photoreceptoral saturated amplitude (Rm P3 ) was reduced (−27%, p<0.05) in diabetic animals (Fig. 1D , unfilled circles) compared with control animals (filled circles). However, no significant change in phototransduction sensitivity (log S) was observed in STZ animals [ Fig. 1E, ANOVA F 3 Consistent with abnormalities in photoreceptoral function, Fig. 2 shows that STZ treatment animals had smaller postreceptoral responses (solid line, unfilled circles) compared with control animals (dashed lines, filled circles). Further, the amplitude of the postreceptoral-P2 response was smaller (p<0.05), whereas implicit times were unaltered (p=0.28) in diabetic rats compared with control rats. Average postreceptoral-P2 amplitude loss in the STZ group was approximately −15% (951.3±45.5 vs 1079.6±31.6 µV), which is smaller than was observed for the photoreceptoral-P3 loss (−27%).
Inner retinal function can also be considered in terms of the oscillatory potentials, which are known to be sensitive indicators of anomalies in diabetic retinae. Figure 3A shows that STZ treatment resulted in changes to the oscillatory potential waveform. The reduction in amplitude is particularly evident and is con- 
lines). C STZ injection (D, • •) lowered OP amplitudes compared with controls (C, •).
Perindopril (D p , ▲ ▲) had no beneficial effect on OP amplitude, whereas aminoguanidine (D a , ■ ■) induced a greater reduction of OP amplitude. Reference lines show mean (solid) and 95% confidence limits (dotted) of the mean control photoreceptoral-P3 amplitude. D OP spread was greater in STZ animals. This effect was ameliorated by perindopril therapy, but not aminoguanidine. E OP peak time was delayed by STZ treatment. Perindopril therapy gave no improvement, whereas aminoguanidine exacerbated the effect. F OP frequency was reduced in STZ animals compared with controls. Perindopril, but not aminoguanidine, returned OP frequency back to within control levels firmed in Fig. 3C , which shows that oscillatory potential amplitudes are smaller (p<0.05) in STZ rats (unfilled circles) compared with control rats (filled circles Perindopril but not amino guanidine restores retinal function in STZ rats. We find that treatment with an ACE inhibitor ameliorates the functional deficits induced by STZ injection in rats. The representative raw data and photoreceptoral-P3 model fits in Fig. 1C shows that perindopril treatment (unfilled triangles, thick lines) gave larger photoreceptoral-P3 responses than aminoguanidine therapy (unfilled squares, thin lines). Fig. 1D and E confirms that perindopril returned photoreceptoral-P3 amplitudes back to control levels (C vs S p ; p=0.94). These amplitudes were better than untreated STZ (p<0.0001) as well as aminoguanidine treated (p<0.001) animals. Indeed, postreceptoral-P2 amplitudes extracted from aminoguanidine treated STZ animals were not significantly improved from untreated diabetic rats (p=0.42). Importantly, perindopril and aminoguanidine when administered to control rats did not alter the electroretinogram. Figures 2 and 3 show that perindopril treated (unfilled triangles) STZ animals benefited from improvement of postreceptoral-P2 amplitudes ( Fig. 2B ; p<0.01) and implicit times ( Fig. 2C; p<0.05 ) compared with untreated STZ (unfilled circles). Perindopril enhanced these parameters to levels comparable to the control (filled circles) group (amplitude; p=0.25, implicit time; p=0.17). Perindopril treatment was unable to improve oscillatory potential amplitudes ( Fig. 3C; p=0 .62) or peak times ( Fig. 3E ; p=0.46) beyond the levels observed for the untreated STZ group. However, oscillatory potential spread ( Fig. 3D; p<0 .0001) and frequency ( Fig. 3F; p<0 .01) improved compared with untreated STZ rats. Hence, perindopril therapy in rats ameliorated the functional deficits induced by STZ induced diabetes. Such improvement was observed in both photoreceptor and inner retinal function.
Aminoguanidine therapy (unfilled squares) in STZ treated animals had no beneficial effect on either postreceptoral-P2 ( Fig. 2B; p=0.92 ) or oscillatory potential ( Fig. 3C; p=0 .62) amplitudes compared with untreated STZ animals (unfilled circles). Indeed, aminoguanidine treatment appeared to make oscillatory potential amplitudes and peak times smaller ( Fig. 3C;  p<0.05) and slower (Fig. 3E; p<0.001 ) respectively, compared with untreated STZ animals. However, an improvement was observed for postreceptoral-P2 implicit times as shown in Fig. 2C (p<0.05) . The different therapeutic effects of perindopril and aminoguanidine could provide information as to the cause of the functional deficits observed in the diabetic retina.
Discussion
Our finding of reduced photoreceptoral-P3 and inner retinal amplitudes provides clear evidence that diabetes results in neural dysfunction. In this study, the photoreceptoral integrity was assayed at a time when little vascular change is manifest [19] and the response was analyzed in terms of the known biochemical cascade of phototransduction [23] . This approach showed that the saturated photoreceptoral-P3 amplitude was smaller in diabetic animals compared with control rats, whereas photoreceptoral sensitivity remains unaffected by diabetes.
Importantly, the reduction in photoreceptoral-P3 amplitude was similar if not greater than was observed for the inner retinal derived postreceptoral-P2 and oscillatory potentials. This outcome is consistent with the idea that inner retinal deficits can arise from photoreceptoral anomalies. A smaller photoreceptoral-P3 response would alter glutamate synaptic signalling and subsequently reduce ON-bipolar cell activation [24, 25] . A similar mechanism can account for the reduction in oscillatory amplitude observed in this study. Additionally, the absence of any reduction in postreceptoral-P2 implicit time further supports the contention that the reduction in postreceptoral-P2 amplitude has a passive mechanism such as that described above.
The reduction in phototransduction amplitude may occur by one of several mechanisms, including: the presence of fewer photoreceptors, a reduced length of the photoreceptor outer segments, fewer cGMP gated cationic channels, or an altered transmembrane ionic gradient. Since anatomical studies of the diabetic rat retina provide no evidence for morphological change or a reduction in photoreceptor numbers, these factors are unlikely to underpin the losses observed in our animals. Additionally, there is no evidence for changes to non-specific cationic channels. In contrast, a reduced Na + -K + ATPase activity has been shown in diabetic rats [16] . Na + -K + ATPase function is responsible for sustaining trans-membrane ionic gradients, so a reduced capacity is consistent with our finding and provides a parsimonious explanation for the functional loss.
This loss is not surprising in a metabolic disease such as diabetes, as the retina has the highest metabolic demand of any tissue [26] and is known to show both vascular and neural compromise in diabetes [3, 27] . The majority of retinal oxygen consumption and adenosine triphosphate (ATP) production supports photoreceptoral function and in particular the dark current [26] . Transport of Na + via Na + -K + ATPases maintains the resting potential of photoreceptors and thereby the dark current, and accounts for nearly half of retinal ATP consumption. Light initiates the phototransduction cascade and reduces this dark current by closure of non-specific cationic channels to induce photoreceptor hyperpolarization, which is measured as the saturated photoreceptor amplitude (Rm P3 ) of the electroretinogram. Hence, Na + -K + ATPase activity is central to phototransduction and any perturbation in its activity will manifest as an altered phototransduction amplitude [28] . It is noteworthy that in diabetes, reduced Na + -K + ATPase activity is observed in a variety of different cell types [29] , including those of the retina [16] .
The basis for the decrease in Na + -K + ATPase activity is unclear and could be caused by altered enzyme kinetics and/or subunit expression. Abnormal expression of Na + -K + ATPase subunits has been reported in the cardiac muscle membranes of diabetic animals [29] , although a change in expression does not seem to occur in the retina [16] . Nevertheless, it is established that the renin-angiotensin system (RAS) and, in particular, that angiotensin-II (AngII), can modulate Na + -K + ATPase activity [30] . The role of the RAS is complex, as AngII stimulates ionic pumps in smooth muscle cells and kidney by activating protein kinase cepsilon (PKC) [31] . As PKC is a well known modulator of Na + -K + ATPase activity [32] , an increased PKC concentration in the diabetic rat retina [33] could contribute to the photoreceptoral dysfunction seen in our animals. These findings suggest that the RAS has a role in the development of diabetic neuropathy by its action either on PKC or directly on Na + -K + ATPases. Notwithstanding this, the nature of RAS involvement remains uncertain given that lowered angiotensin converting-enzyme (ACE) activity has been detected in the retina of diabetic rats, even with increased serum ACE [34] .
In spite of conflicting evidence, we conclude that the RAS system must contribute in some way to retinal dysfunction in diabetic rats as ACE inhibition returns normal photoreceptoral and inner retinal amplitudes in the diabetic group. All physiological parameters were improved in the treated cohort, although only functional parameters were normalized to control levels. Perindopril treatment had no effect on parameters in control animals.
Perindopril is a potent antihypertensive drug, however we do not believe that a reduction in blood pressure underlies the functional improvement found with perindopril. In support of this contention, improvement of oscillatory potential deficits was only achievable using an ACE inhibitor, despite similar reductions in blood pressure with a calcium antagonist and a beta-blocker [35] . Instead, we posit that the effect involves an altered Na + -K + ATPase activity in the diabetic retina [34] . We note that the ACE inhibitor, captopril, is known to restore retinal Na + -K + ATPase activity in diabetic rats [16] . Specifically, captopril stimulates Na + -K + ATPase activity in the neural retina but not the retinal pigment epithelium of diabetic animals [36] .
In order to consider the hypothesis that perindopril has a neuromodulatory action in the retina, we contrast its effect against that found with an inhibitor of advanced glycation end product (AGE) formation. Aminoguanidine, prevents glucose-dependent non-enzymatic AGE accumulation, which stops the activation of AGE specific receptors and subsequently reduces many deleterious actions including the formation of cytokines [37, 38] . However, aminoguanidine may have some neuroprotective actions through inhibition of nitric oxide formation [39, 40] , as evidenced by the reduction in ganglion cell loss attenuated in an animal model of glaucoma [41] . Despite these benefits of aminoguanidine [38, 39, 40, 41] , we were unable to show an improvement of functional amplitudes in diabetic rats, even though physiological parameters were improved. The absence of any functional improvement with aminoguanidine treatment provides indirect evidence for a lack of patent vasculopathy in our diabetic rats as this is the expected locus of aminoguanidine action. Moreover, the common physiological changes found with both drugs would imply some common vascular mechanism. These findings also suggest that perindopril ameliorates photoreceptor deficits in the diabetic retina through a neuromodulatory route rather than involving the vascular endothelium.
A caveat to this interpretation is that the lower blood pressure and HBA 1c levels that can occur with perindopril can contribute to the improved retinal function in this group of treated diabetic animals. We argue above that any improvement in blood pressure is likely to play a minor role. In contrast, improved hyperglycaemic control indicated by lower HBA 1c could contribute to the observed functional improvement, as the severity of diabetic complication has been associated with the degree of hyperglycaemia [42] . This issue requires further consideration as retinal function is normalized with perindopril treatment, while HBA 1c remains twice that of control animals.
Our study advances the outcomes of the HOPE [43] and EUCLID study group [44] multi-centre trials, which show that ACE inhibition lowers the risk of diabetic complications. Our findings suggest that ACE inhibition can directly modulate neuronal as well as vascular function. It also supports the proposal that early intervention in diabetics with ACE inhibitors will be a useful addition to current management strategies.
